Loading organizations...
Huayi Capital, an entity whose core business activities and geographical headquarters are not publicly detailed, operates with an undisclosed focus within the financial landscape. Information regarding its specific business model, operational scale, and target market segments remains largely unavailable in public records, preventing a clear understanding of its strategic positioning. The organization has not disclosed specific financial figures, such as total funding raised, its current assets under management (AUM), or an estimated valuation, leaving its financial footprint opaque. Similarly, there is no public identification of prominent lead investors, notable portfolio companies, or significant customers it serves, making its network and impact difficult to assess. Details concerning its establishment, including the precise founding year and the names of its original founders, are also not publicly accessible through standard industry databases or corporate registries.
Huayi Capital has 2 tracked investments across 2 companies. The latest tracked deal is $1.3M Series A in Juncell Therapeutics in January 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 15, 2022 | Juncell Therapeutics | $1.3M Series A | — | BioVenture, Huaige Capital, Huangpu Medical Fund, Kaitai Capital |
| Oct 13, 2021 | Laviana Pharma | $77.5M Series C | — | October Capital |